BZYR - Burzynski Research Institute, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Burzynski Research Institute, Inc.

9432 Katy Freeway
Houston, TX 77055
United States

IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Stanislaw R. Burzynski M.D., Ph.D.Chairman, Chief Exec. Officer and PresN/AN/A1943
Mr. Patryk P. Goscianski M.B.A.Treasurer and Sec.N/AN/A1978
Dr. Tomasz Janicki M.D.VP of Clinical TrialsN/AN/A1966
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Burzynski Research Institute, Inc. operates a research and development facility of drugs used in the treatment of cancer in the United States. The company focuses on the research, development, production, marketing, promotion, and sale of medical chemical compounds, such as growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also provides consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.

Corporate Governance

Burzynski Research Institute, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.